Cargando…

Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) has poor prognosis with limited treatment options, with little therapeutic progress made during the past several decades. DNA damage response (DDR) associated therapies, including radiation and inhibitors of DDR, demonstrate potential efficacy against TNBC, espec...

Descripción completa

Detalles Bibliográficos
Autores principales: Clark, Curtis A., Yang, Eddy S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497895/
https://www.ncbi.nlm.nih.gov/pubmed/34631532
http://dx.doi.org/10.3389/fonc.2021.703802
_version_ 1784580060805595136
author Clark, Curtis A.
Yang, Eddy S.
author_facet Clark, Curtis A.
Yang, Eddy S.
author_sort Clark, Curtis A.
collection PubMed
description Triple-negative breast cancer (TNBC) has poor prognosis with limited treatment options, with little therapeutic progress made during the past several decades. DNA damage response (DDR) associated therapies, including radiation and inhibitors of DDR, demonstrate potential efficacy against TNBC, especially under the guidance of genomic subtype-directed treatment. The tumor immune microenvironment also contributes greatly to TNBC malignancy and response to conventional and targeted therapies. Immunotherapy represents a developing trend in targeted therapies directed against TNBC and strategies combining immunotherapy and modulators of the DDR pathways are being pursued. There is increasing understanding of the potential interplay between DDR pathways and immune-associated signaling. As such, the question of how we treat TNBC regarding novel immuno-molecular strategies is continually evolving. In this review, we explore the current and upcoming treatment options of TNBC in the context of DNA repair mechanisms and immune-based therapies, with a focus on implications of recent genomic analyses and clinical trial findings.
format Online
Article
Text
id pubmed-8497895
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84978952021-10-09 Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer Clark, Curtis A. Yang, Eddy S. Front Oncol Oncology Triple-negative breast cancer (TNBC) has poor prognosis with limited treatment options, with little therapeutic progress made during the past several decades. DNA damage response (DDR) associated therapies, including radiation and inhibitors of DDR, demonstrate potential efficacy against TNBC, especially under the guidance of genomic subtype-directed treatment. The tumor immune microenvironment also contributes greatly to TNBC malignancy and response to conventional and targeted therapies. Immunotherapy represents a developing trend in targeted therapies directed against TNBC and strategies combining immunotherapy and modulators of the DDR pathways are being pursued. There is increasing understanding of the potential interplay between DDR pathways and immune-associated signaling. As such, the question of how we treat TNBC regarding novel immuno-molecular strategies is continually evolving. In this review, we explore the current and upcoming treatment options of TNBC in the context of DNA repair mechanisms and immune-based therapies, with a focus on implications of recent genomic analyses and clinical trial findings. Frontiers Media S.A. 2021-09-24 /pmc/articles/PMC8497895/ /pubmed/34631532 http://dx.doi.org/10.3389/fonc.2021.703802 Text en Copyright © 2021 Clark and Yang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Clark, Curtis A.
Yang, Eddy S.
Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer
title Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer
title_full Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer
title_fullStr Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer
title_full_unstemmed Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer
title_short Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer
title_sort harnessing dna repair defects to augment immune-based therapies in triple-negative breast cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497895/
https://www.ncbi.nlm.nih.gov/pubmed/34631532
http://dx.doi.org/10.3389/fonc.2021.703802
work_keys_str_mv AT clarkcurtisa harnessingdnarepairdefectstoaugmentimmunebasedtherapiesintriplenegativebreastcancer
AT yangeddys harnessingdnarepairdefectstoaugmentimmunebasedtherapiesintriplenegativebreastcancer